---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000159"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:29:31.361826+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q3 cash $280.7M, cuts R&D spend 37% YoY; DENALI trial on track for data by YE2026

## Summary
- Cash and marketable securities $280.7M as of Sep 30, 2025; runway into late 2027.
- R&D expenses $23.0M in Q3 2025, down 37.5% from $36.8M in Q3 2024.
- G&A expenses $10.8M, down 26% from $14.6M YoY.
- Phase 2 DENALI trial of azenosertib in Cyclin E1-positive PROC on track; topline data expected by year end 2026, potentially supporting accelerated approval.
- TETON Phase 2 in USC completed enrollment; further development limited to partnering or capital allocation.

## SEC filing metadata
- accession: 0001725160-25-000159
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/0001725160-25-000159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/zntl-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000159
- JSON: https://secwatch.observer/filing/0001725160-25-000159.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.